

MEDIA RELEASE

Novartis announces removal of Denagard® Liquid Concentrate weight restrictions

- *Producers now allowed to combat diseases with Denagard Liquid Concentrate in pigs weighing more than 250 pounds*

Greensboro, NC (August 25, 2008) — Pork producers can now use Denagard® (tiamulin) Liquid Concentrate to combat costly diseases in pigs weighing more than 250 pounds. The Food and Drug Administration recently accepted the removal of the weight limit.

“Denagard is a broad-spectrum solution for many of the diseases that the swine industry is facing today. It is effective in pigs and market hogs of all ages, and now with the weight restriction removed, producers can use the product to control disease in animals weighing more than 250 pounds,” says Sean O’Hare, pig and poultry sales manager for the Novartis U.S. farm animal business.

Denagard is approved to treat swine pneumonia caused by *Actinobacillus pleuropneumoniae* and swine dysentery. Response is usually evident in 24 to 48 hours as tiamulin is readily absorbed from the gut and can be found in the blood within 30 minutes after dosing.

As always, be sure to follow label directions and required withdrawal times. For more information, contact Novartis at 1-800-843-3386 or visit www.livestock.novartis.com.

Caution: Do not feed undiluted. Do not use in feeds for animals other than swine. The effects of tiamulin on swine reproductive performance, pregnancy and lactation have not been determined.

About Novartis Animal Health

Novartis Animal Health researches, develops and commercializes leading animal treatments that meet the needs of pet owners, farmers and veterinarians. Headquartered in Basel, Switzerland, Novartis Animal Health conducts business in 40 countries and employs about 2,700 people worldwide. For more information, please consult www.ah.novartis.us.

About Novartis

Novartis AG provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools and consumer health products. Novartis is the only company with leading positions in these areas. In 2007, the Group’s continuing operations (excluding divestments in 2007) achieved net sales of USD 38.1 billion and net income of USD 6.5 billion. Approximately USD 6.4 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 98,000 full-time associates and operate in over 140 countries around the world. For more information, please visit <http://www.novartis.com>.

###

Novartis Animal Health Media Relations

Joseph Burkett

Novartis Animal Health Communications

(336) 387-1006 (direct)

(336) 209-4887 (mobile)

joseph.burkett@novartis.com

Julie Groce

Novartis Animal Health Communications

(336) 387-1080 (direct)

(336) 601-8079 (mobile)

julie.groce@novartis.com